Jawad Muayad, Asad Loya, Zain S Hussain, Debora H Lee, Muhammad Z Chauhan, Andrew G Lee, Asadolah Movahedan, Sami S Dahr
{"title":"常用药物对2型糖尿病黄斑水肿的影响。","authors":"Jawad Muayad, Asad Loya, Zain S Hussain, Debora H Lee, Muhammad Z Chauhan, Andrew G Lee, Asadolah Movahedan, Sami S Dahr","doi":"10.1016/j.oret.2024.12.006","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the impact of systemic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), fenofibrates, thiazolidinediones (TZDs), and calcium channel blockers (CCBs), on the risk of developing diabetic macular edema (DME) in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Design: </strong>A retrospective cohort study was conducted using electronic medical records (EMR) data from the TriNetX health research network, covering a period from October 2004 to 2024.</p><p><strong>Participants: </strong>The study population comprised patients diagnosed with T2DM who were newly initiated on GLP-1 RAs, fenofibrates, TZDs, or CCBs. Propensity score matched (PSM) controls were patients with T2DM who did not receive these medications within the same timeframe.</p><p><strong>Methods: </strong>Patients were observed for 1 to 2 years postmedication initiation to monitor the development of DME. The study used 1:1 propensity score matching to adjust for baseline characteristics and comorbidities.</p><p><strong>Main outcome measures: </strong>The primary outcome measure was the incidence rate of DME within the 2-year follow-up period. Hazard ratios (HRs) with 95% confidence interval (CI) were calculated to compare the risk of DME between treatment and control groups.</p><p><strong>Results: </strong>After PSM, the study analyzed data from 107 193 patients in the CCB cohort, 76 583 in the GLP-1 agonists cohort, 25 657 in the TZDs cohort, and 18 606 in the fenofibrates cohort. Calcium channel blocker-treated patients demonstrated a higher risk of DME development compared with controls (HR: 1.66, 95% CI: 1.54-1.78). In contrast, GLP-1 RA-treated patients showed a decreased risk of DME (HR: 0.77, 95% CI: 0.70-0.85), as did fenofibrate-treated patients (HR: 0.83, 95% CI: 0.68-0.98). No significant difference in DME risk was observed in the TZDs cohort (HR: 1.08, 95% CI: 0.94-1.25).</p><p><strong>Conclusions: </strong>Patients on GLP-1 RAs and fenofibrates experienced a lower risk of DME diagnosis, suggesting a protective effect against DME development in patients with T2DM, whereas those on CCBs experienced an increased risk. These findings suggest that systemic medications may significantly influence DME outcomes, warranting further investigation into their effects on retinal health.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus.\",\"authors\":\"Jawad Muayad, Asad Loya, Zain S Hussain, Debora H Lee, Muhammad Z Chauhan, Andrew G Lee, Asadolah Movahedan, Sami S Dahr\",\"doi\":\"10.1016/j.oret.2024.12.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to assess the impact of systemic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), fenofibrates, thiazolidinediones (TZDs), and calcium channel blockers (CCBs), on the risk of developing diabetic macular edema (DME) in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Design: </strong>A retrospective cohort study was conducted using electronic medical records (EMR) data from the TriNetX health research network, covering a period from October 2004 to 2024.</p><p><strong>Participants: </strong>The study population comprised patients diagnosed with T2DM who were newly initiated on GLP-1 RAs, fenofibrates, TZDs, or CCBs. Propensity score matched (PSM) controls were patients with T2DM who did not receive these medications within the same timeframe.</p><p><strong>Methods: </strong>Patients were observed for 1 to 2 years postmedication initiation to monitor the development of DME. The study used 1:1 propensity score matching to adjust for baseline characteristics and comorbidities.</p><p><strong>Main outcome measures: </strong>The primary outcome measure was the incidence rate of DME within the 2-year follow-up period. Hazard ratios (HRs) with 95% confidence interval (CI) were calculated to compare the risk of DME between treatment and control groups.</p><p><strong>Results: </strong>After PSM, the study analyzed data from 107 193 patients in the CCB cohort, 76 583 in the GLP-1 agonists cohort, 25 657 in the TZDs cohort, and 18 606 in the fenofibrates cohort. Calcium channel blocker-treated patients demonstrated a higher risk of DME development compared with controls (HR: 1.66, 95% CI: 1.54-1.78). In contrast, GLP-1 RA-treated patients showed a decreased risk of DME (HR: 0.77, 95% CI: 0.70-0.85), as did fenofibrate-treated patients (HR: 0.83, 95% CI: 0.68-0.98). No significant difference in DME risk was observed in the TZDs cohort (HR: 1.08, 95% CI: 0.94-1.25).</p><p><strong>Conclusions: </strong>Patients on GLP-1 RAs and fenofibrates experienced a lower risk of DME diagnosis, suggesting a protective effect against DME development in patients with T2DM, whereas those on CCBs experienced an increased risk. These findings suggest that systemic medications may significantly influence DME outcomes, warranting further investigation into their effects on retinal health.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oret.2024.12.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2024.12.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus.
Purpose: This study aimed to assess the impact of systemic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), fenofibrates, thiazolidinediones (TZDs), and calcium channel blockers (CCBs), on the risk of developing diabetic macular edema (DME) in patients with type 2 diabetes mellitus (T2DM).
Design: A retrospective cohort study was conducted using electronic medical records (EMR) data from the TriNetX health research network, covering a period from October 2004 to 2024.
Participants: The study population comprised patients diagnosed with T2DM who were newly initiated on GLP-1 RAs, fenofibrates, TZDs, or CCBs. Propensity score matched (PSM) controls were patients with T2DM who did not receive these medications within the same timeframe.
Methods: Patients were observed for 1 to 2 years postmedication initiation to monitor the development of DME. The study used 1:1 propensity score matching to adjust for baseline characteristics and comorbidities.
Main outcome measures: The primary outcome measure was the incidence rate of DME within the 2-year follow-up period. Hazard ratios (HRs) with 95% confidence interval (CI) were calculated to compare the risk of DME between treatment and control groups.
Results: After PSM, the study analyzed data from 107 193 patients in the CCB cohort, 76 583 in the GLP-1 agonists cohort, 25 657 in the TZDs cohort, and 18 606 in the fenofibrates cohort. Calcium channel blocker-treated patients demonstrated a higher risk of DME development compared with controls (HR: 1.66, 95% CI: 1.54-1.78). In contrast, GLP-1 RA-treated patients showed a decreased risk of DME (HR: 0.77, 95% CI: 0.70-0.85), as did fenofibrate-treated patients (HR: 0.83, 95% CI: 0.68-0.98). No significant difference in DME risk was observed in the TZDs cohort (HR: 1.08, 95% CI: 0.94-1.25).
Conclusions: Patients on GLP-1 RAs and fenofibrates experienced a lower risk of DME diagnosis, suggesting a protective effect against DME development in patients with T2DM, whereas those on CCBs experienced an increased risk. These findings suggest that systemic medications may significantly influence DME outcomes, warranting further investigation into their effects on retinal health.
Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
